WASHINGTON – This week, Reps. Madeleine Dean and Marc Veasey (TX-33) re-introduced H.R. 1629, the Fairness in Orphan Drug Exclusivity Act.
The bill closes a loophole that could be used to block pharmaceutical competition and prevents innovative treatments for opioid use disorder from coming to market.
“The Fairness in Orphan Drug Exclusivity Act will eliminate barriers for innovative medication assisted treatments (MAT) to come to market, boost competition in the marketplace, and drive down the cost of new medicines,” Rep. Dean said.
“Each year, the opioid crisis impacts millions of families in every crevice of our country,” said Rep. Veasey. “The Fairness in Orphan Drug Exclusivity Act will help us curb the loss of life by expanding access to a wide range of new medication-assisted treatments that will create more options in the marketplace.”
For decades, The Orphan Drug Act of 1983 has provided incentives for prescription drug manufacturers to develop products to treat rare diseases — including an exclusive seven-year marketing right for therapies that receive an orphan drug indication.
For a drug to qualify for orphan designation, certain criteria must be met:
The disease or condition for which the drug is intended affects fewer than 200,000 people in the United States; or
For diseases or conditions affecting 200,000 or more people, there is no reasonable expectation that costs of research and development (R&D) of the drug can be recovered through sales.
Because opioid use disorder affects millions of Americans, the first criterion does not apply to new opioid medications.
However, a loophole allows manufacturers to obtain seven-year market exclusivity under the second criterion by “piggybacking” on the orphan drug status of an older drug – even if they expect to easily recoup their R&D costs on the new version.
The Fairness in Orphan Drug Exclusivity Act would close this loophole by making a minor update to the Orphan Drug Act – requiring all drugs that obtain seven years of market exclusivity under the second criterion to show that they have no reasonable expectation of recovering R&D costs through sales in the United States.
Rep. Madeleine Dean is a mother, grandmother, attorney, professor, former four-term member of the Pennsylvania House of Representatives, and U.S. Representative for the Fourth District of Pennsylvania.